0,deacetylases
1,maladaptive
2,cardiology
3,event rate
4,therapy
5,stand-alone
6,due
7,co-morbidities
8,non-survivors
9,advantage
10,extending
11,dialysis-dependent
12,actions
13,antiplatelet agents
14,cytoskeletal
15,relevance
16,signalling
17,improved survival
18,breathlessness
19,cause of death
20,documented
21,pg
22,cs
23,adverse events
24,measure
25,self-care
26,filling pressure
27,cardioverter-defibrillators
28,serious
29,adhesion genes
30,safe
31,p=0.02
32,meta-analysis
33,centers
34,driven
35,myxoma
36,paediatric
37,undiagnosed
38,deciles
39,tissues
40,surgical intervention
41,health systems
42,blood testing
43,tachycardia-induced
44,receptors
45,muscle
46,evolution
47,changes
48,response
49,health-related
50,control group
51,endothelial
52,reduction
53,low-quality
54,tac
55,change in c-index
56,tracking
57,hretn
58,measuring
59,interventions
60,progenitors
61,middle-aged
62,frame
63,approach
64,primary outcome
65,vagal
66,annuloplasty
67,sequence
68,reversed
69,clinical practice
70,confounded
71,proof-of-principle
72,devices
73,leg
74,pulse
75,mlhf
76,ejection time
77,two
78,defibrillator-only
79,leading
80,subgroups
81,strong
82,obstructed
83,colony-forming units
84,transforming
85,confidence interval
86,immunoprecipitation
87,lvet
88,capacity
89,bradyarrhythmias
90,healthcare
91,activate
92,nbdmards
93,admissions
94,circulatory failure
95,end-stage
96,subgroup
97,angiotensin-aldosterone
98,per se
99,sample
100,processed
101,etiologic
102,effects
103,extracorporeal
104,muscles
105,transition
106,hemodynamic perturbations
107,difference
108,contractile reserve
109,adenine
110,extracted
111,further investigation
112,assessed
113,involving
114,non-lbbb
115,protocol-driven
116,cyclic
117,end stage
118,recent
119,flow
120,feeding
121,language
122,lean
123,pharmaceuticals
124,saf
125,higher-than-expected
126,young woman
127,subproteome
128,prediction rule
129,length of stay
130,oxygen
131,adenosine
132,measurement
133,2-erk1
134,normal geometry
135,concentrations
136,large trial
137,mo
138,evaluating
139,hf-induced
140,seven
141,decades
142,adenylyl
143,debilitating
144,markers
145,hospitalizations
146,expression
147,aerobic
148,show
149,sternal
150,va-rt
151,natriuretic
152,wall
153,inhibitors
154,success rate
155,renin-angiotensin
156,an
157,depressed
158,receptor
159,subtle changes
160,catabolic
161,non-randomized
162,resonance
163,agent
164,spent
165,overlapped
166,arthritis
167,walk
168,again
169,poses
170,beneficiaries
171,hallmark
172,fail
173,hospital quality of care
174,ratio
175,accompanied
176,stress
177,outcome-monitoring
178,hhd
179,center
180,early-activated
181,single
182,haplotype
183,cytotoxic
184,defence
185,rv
186,right
187,all-cause
188,months
189,over
190,features
191,atherosclerotic
192,collected
193,postoperative mortality
194,unilateral
195,accounting
196,unfolded
197,exerts
198,database
199,adjustment
200,sympathetic
201,discharges
202,cumulative
203,nervous systems
204,right heart failure
205,medicare
206,defibrillator-crt
207,longitudinal
208,longitudinal strain
209,medium
210,surgical conditions
211,abdominal
212,pacemaker
213,resection
214,unaltered
215,ans
216,beat
217,pure epicatechin
218,intubated
219,exchanges
220,protection
221,thus
222,antiplatelet drugs
223,baroreflex
224,series
225,propensity-score
226,imaging
227,found
228,detection
229,myocardium
230,deaths
231,extend
232,variation
233,haemodynamic stress
234,defense mechanism
235,conducting
236,validity
237,reports
238,differentiation
239,two-center
240,pathogenesis
241,first-in-man
242,trend
243,longitudinal analysis
244,constriction
245,unanchors
246,policy
247,anti-inflammatory effects
248,congenital
249,resolution
250,potassium
251,atheromatous
252,6mwt
253,high-dose
254,tension
255,financial costs
256,changes in
257,counterbalance
258,pathways
259,palliative care
260,her
261,kidney failure
262,hospitalization rates
263,but
264,acute care
265,improvement
266,myocytes
267,patterns
268,diabetes mellitus
269,small-molecule
270,decision-support
271,multiorgan failure
272,medication regimen
273,standard error
274,infusions
275,endpoints
276,20-week
277,venoarterial dilation
278,cgmp
279,background
280,overview
281,ctnt
282,inhibition
283,networks
284,rare
285,antitumor
286,heart failure
287,well
288,study
289,bhlh
290,reference lists
291,problems
292,by
293,renin-angiotensin-aldosterone
294,hospital
295,plateau
296,systole
297,compensatory
298,deactivation
299,tested
300,confounding
301,stiffness
302,tissue
303,clinical outcome
304,reclassification
305,hepatic
306,findings
307,left-hand
308,clinical outcomes
309,transoesophageal
310,inverse
311,myocarditis
312,elevations
313,intermuscular
314,postoperative survival
315,deranged
316,patterning
317,power index
318,srd
319,congestion
320,infarct
321,decreased
322,inpatient records
323,actin
324,wasting
325,referral
326,full-length
327,obstructive
328,contractile function
329,prospective
330,valvular
331,shams
332,apex
333,contention
334,heart disease
335,unsuccessful
336,control
337,further examination
338,biomarkers
339,non-fatal stroke
340,office hours
341,c-kit
342,confer
343,duration
344,sham
345,cogeneration
346,consultations
347,design
348,upregulated
349,obtained
350,differences
351,myocardial tissue
352,read
353,pulse-wave
354,demonstrate
355,metabolic changes
356,given
357,empirically
358,covariates
359,model
360,air pollution
361,hypertension
362,turned on or off
363,embolism
364,study end point
365,breathing
366,target
367,reduced
368,non-dnx
369,further
370,lv
371,intermediate care
372,camp
373,process
374,resistin levels
375,report
376,demographic changes
377,620 feet
378,outline
379,leads
380,peak vo2
381,pay-for-performance
382,haematopoietic
383,random-effects
384,antiadrenergic
385,underlying mechanism
386,long-term mortality
387,post-myocardial
388,at the point of care
389,controlled
390,ethnicity
391,content-driven
392,abnormal chamber
393,agents
394,time-domain
395,blocker
396,platelet-activating
397,nontrastuzumab
398,sts
399,risks
400,nontraumatic
401,progenitor
402,period
403,turnaround times
404,flow-mediated
405,longitudinal change
406,anthracycline-containing
407,black
408,post-tac
409,baseline
410,sex
411,readmissions
412,icu
413,peripheral
414,admissions per patient
415,clinical trial
416,diameter
417,iron
418,increases
419,transitions
420,barriers to participation
421,p38alpha
422,statistics
423,post
424,below
425,signalosome
426,challenges
427,savings
428,emergency department
429,conclusions
430,30-day
431,anthracycline-induced
432,clinician
433,practice
434,chelation
435,reserve
436,discharged
437,elderly
438,profound change
439,rr
440,percutaneous
441,medical records
442,passive
443,brain
444,guidelines
445,triggered
446,modestly
447,congenital abnormalities
448,visits
449,promising
450,hospitalization
451,dipeptidyl
452,single-arm
453,further influences
454,nonprescribing
455,economic
456,website
457,haemodynamic
458,mice
459,lessons for nurse leaders
460,work rate
461,surgical
462,infarction
463,time of discharge
464,natural
465,applicable
466,atrium
467,asymptomatic
468,strategy
469,large-scale
470,oxygenation on renal function
471,aggravate
472,system
473,measurement value
474,channels
475,ami
476,enrichment analysis
477,newly
478,poorer
479,collateral
480,wall stress
481,in
482,overexpression
483,reviewed
484,acting
485,extended
486,non-sudden
487,preoperative
488,unfit
489,disseminate
490,commissioning
491,follow-up visits
492,molecular level
493,lead
494,rhythm
495,denotes
496,man
497,tachycardia
498,excised
499,burden
500,tests
501,relationship
502,x12
503,slows
504,auscultation
505,readmission rate
506,sport
507,driveline
508,tolerance
509,visit
510,diastole
511,ischemic
512,independently
513,sternotomy
514,resting hr
515,accountable
516,simpler
517,alternatives
518,transverse aortic
519,demonstrating
520,post-lvad
521,multisite
522,subproteomes
523,per os
524,compelling
525,presents
526,signs
527,contact
528,drug
529,dearth
530,left bundle
531,ckd
532,fluid
533,cases
534,nbdmard
535,case
536,evidence
537,bb
538,changes in treatment
539,time span
540,induced
541,ankle-brachial index
542,recipients
543,p=0Â·035
544,training
545,double mutant
546,surgically
547,yielded
548,al
549,bound
550,body
551,senescence
552,anthracycline-related
553,resting
554,nps
555,frail
556,retention
557,qt
558,phosphorylation capacity
559,self-identified
560,common
561,de
562,recommendation
563,abundance
564,methods
565,inputs
566,point of care
567,despite
568,abnormalities
569,infusion
570,co-activating
571,measurement systems
572,regression
573,activating
574,calculated
575,internal diameter
576,delivery
577,reference
578,histologic
579,etiology
580,pathological changes
581,human
582,antiarrhythmic drugs
583,strain
584,aged
585,hfpef
586,lcx
587,duplicate
588,first
589,descriptive
590,sources
591,interest
592,cardioverter-defibrillator
593,advisors
594,intubations
595,white
596,clinical trials
597,high-frequency
598,vitro
599,transcription
600,patients above the median
601,competitive
602,time to death
603,demographic
604,ventricular dysfunction
605,suppresses
606,blockade
607,muscular
608,length-force
609,common conditions
610,hfpsi
611,incidence
612,wave
613,enriched
614,pigs
615,cohort
616,referrals
617,re-express
618,tachypacing-induced
619,myocardial perfusion
620,opening
621,borderline
622,transcript
623,individual
624,heart failure center
625,studies
626,threshold
627,cardiac arrest
628,failure
629,hospitalized
630,reactivation
631,inappropriate
632,health service
633,bets
634,standard
635,curves
636,weight loss
637,etidronate
638,interatrial shunting
639,abnormal
640,index
641,cox
642,endothelin
643,taxonomy
644,latter
645,dna
646,severely
647,equation
648,subspecialty groups
649,cohorts
650,transcatheter
651,postmenopausal
652,ivabradine
653,encoding
654,under
655,short
656,characteristics
657,costing
658,definition
659,accounted
660,new
661,forward
662,therapeutic
663,outpatient
664,change in distribution
665,atrial structure
666,test
667,rehospitalization
668,initiative
669,cost
670,encouraging
671,performers
672,beginning
673,late-activated
674,cardiac
675,society
676,clinical care
677,circulation
678,core
679,midpapillary
680,confirmed
681,pharmaceutically
682,allocation
683,medical conditions
684,pacemakers
685,limbs
686,fear
687,health-care budget
688,norepinephrine
689,atrial fibrillation
690,mixed-methods
691,matched
692,diastolic
693,coprimary
694,consultation
695,basis
696,spironolactone
697,p=0.004
698,acetylcholinesterase
699,sci
700,left
701,single-cohort
702,resource
703,gadolinium-chelate
704,risk-adjusted
705,pef
706,codes
707,quality-of-life
708,breathing control
709,extensive
710,schfi
711,complexities
712,carcinoma
713,combined care
714,ip
715,caring
716,warranted
717,nonfatal
718,died
719,socioeconomic
720,pad
721,forty-six
722,moderate
723,s'lateral
724,newer
725,acute
726,explant
727,formalism
728,evident
729,decreases
730,subvalvular
731,responses
732,hf
733,panel
734,permeability
735,signal
736,reclassified
737,hgb level
738,translocation
739,reperfusion
740,assessments
741,elicited
742,postoperatively
743,atherosclerosis
744,collateral growth
745,rabbits
746,harms
747,addition
748,redesigned
749,preoperative serum
750,enrollment periods
751,life expectancy
752,antibodies
753,attenuation
754,participants
755,as
756,decongestion
757,third heart
758,preceding mechanisms
759,clinical studies
760,outcomes
761,uninephrectomy
762,derangement
763,hospitalisations
764,general
765,exhibit
766,abstract
767,splicing
768,histologically
769,without
770,triggers
771,discharge
772,active
773,sought
774,transduction
775,worst
776,implants
777,fever
778,conditioning
779,adult
780,endpoint
781,rheumatic
782,pyridostigmine
783,subclinical
784,inpatient
785,oversewing
786,nonpublic
787,pulse sequence
788,iron deficiency
789,computed
790,antiplatelet
791,circumflex
792,link
793,long-term effects
794,crt
795,yields
796,significant
797,reasons
798,free wall
799,reactivate
800,rrna
801,air
802,detecting
803,resistance
804,life-threatening
805,undertaken
806,noted
807,knockdown
808,questions
809,responsive
810,euthanization
811,reassessed
812,frailty
813,protective
814,post-translational
815,transgenic mice
816,cornerstone
817,nursing
818,antiarrhythmic
819,recommend
820,identification
821,breakdown
822,explants
823,nonselective
824,review
825,statistical
826,critical
827,thigh
828,programme
829,vector
830,acetyltransferases
831,analysis
832,sudden
833,enhancement imaging
834,adherence
835,recommendations
836,demonstrated
837,consumption rate
838,growth factor
839,measured
840,fatigue
841,inpatient admissions
842,inflammation
843,pre-post
844,uptake
845,per cent
846,sub-sample
847,alternative
848,noncardiologist
849,resonance imaging
850,leaflet
851,setting
852,parallel-group
853,prostate
854,importance
855,interpretation
856,crossover
857,transfusions
858,long-term
859,atrioventricular delay
860,time frame
861,cation
862,exacerbates
863,explanted
864,fibrillation
865,fee-for-service
866,alendronate
867,assessment
868,hypokalemia
869,hazards
870,risk of death
871,hm
872,metoprolol
873,congestion-like
874,histone
875,rheumatoid
876,congestive heart failure
877,nonadherence
878,minutes
879,strokes
880,myocardial changes
881,end point
882,pro-b-type
883,protocol
884,ejection
885,subunit
886,sepsis
887,surrogate
888,elevated
889,tachyarrhythmias
890,surviving
891,reoperation
892,emean
893,training-induced
894,die
895,toxicity
896,chelation regimens
897,procedural
898,deposition
899,gating
900,inhibitor
901,context
902,rats
903,side effects
904,functional capacity
905,exercise
906,on
907,balance
908,brief
909,referred
910,aiming
911,ras
912,signaling pathway changes
913,major
914,negative
915,administration
916,activation sequence
917,aortic
918,4Â±15 bpm
919,renal
920,periprocedural deaths
921,multiple myeloma
922,readmission
923,af
924,followed-up
925,step
926,hospital admissions
927,income per capita
928,increased
929,effective
930,length
931,distressing
932,malfunctions
933,reported
934,cytochrome
935,width
936,chemotherapy
937,calf
938,defibrillators
939,perfusion
940,time of inclusion
941,counterparts
942,support
943,shortens
944,admission
945,induction
946,results
947,hhf
948,pressure
949,propensity
950,dynamic
951,anticoagulants
952,sustainability
953,trial
954,whites
955,canine
956,atrial pressure
957,participant
958,sulfonylureas
959,test-retest
960,myoctyes
961,consumes
962,hospital length
963,counted
964,program
965,analyzed
966,legal majority
967,two-vessel
968,ste
969,inability
970,drawn
971,reporting
972,main effect
973,confidence level
974,unknown
975,clinicians
976,general populations
977,expansion protocols
978,channel
979,absorptiometry
980,intervals
981,wk
982,diet adherence
983,substudy
984,initiated
985,glucose
986,dynamics
987,placebo-treated
988,hospitals
989,mechanisms
990,extracellular matrix
991,monitoring board
992,uncertain
993,subjects
994,long-acting
995,fat
996,subunits
997,hipsc-cms
998,non-urbanized
999,preserve
1000,right ventricular
1001,abrogated
1002,dd
1003,refractory
1004,unstable
1005,resistin
1006,risk--the
1007,thrombosis
1008,nursing facilities
1009,after
1010,network
1011,untreated
1012,mediator
1013,causes of death
1014,authors
1015,lung
1016,follow-up levels
1017,prone
1018,thromboembolism
1019,analyze
1020,closure
1021,noncardiac
1022,date of death
1023,clinically
1024,shunt
1025,emission
1026,injury
1027,double-blind trial
1028,going
1029,adjuvant
1030,action potential
1031,pro-brain
1032,systolic
1033,mediated
1034,end
1035,cardioprotection
1036,budget
1037,tachycardic
1038,fm
1039,criteria
1040,exercise per week
1041,witness
1042,interplay
1043,pressure-overload
1044,pathway analysis
1045,shorter
1046,free mass
1047,sympathovagal
1048,arrest
1049,donors
1050,anthracyclines
1051,unloads
1052,subscales
1053,cpr
1054,blood pressure
1055,end diameter
1056,staff
1057,inducing
1058,nontreatment
1059,underlies
1060,peptides
1061,central venous
1062,ffm
1063,expenditure
1064,immunoassays
1065,assisted
1066,patients
1067,change in clinical status
1068,attenuated
1069,chf
1070,faced
1071,reveal
1072,looping
1073,regression line
1074,re-activating
1075,ml
1076,exertional increase
1077,quality of life
1078,camp-dependent
1079,contracting
1080,'d
1081,hand-searching
1082,evaluation
1083,programmes
1084,guideline
1085,individuals
1086,assay
1087,left ventricular function
1088,density
1089,furosemide
1090,resynchronization
1091,disappointments
1092,further studies
1093,etiologies
1094,brachial
1095,strength
1096,across-the-board
1097,attributable
1098,p70s6k
1099,benefit
1100,action
1101,age groups
1102,protective peptides
1103,tolvaptan
1104,nervous
1105,combinations
1106,assist
1107,attrition
1108,regurgitation
1109,assays
1110,motion
1111,malfunctioning
1112,btt
1113,diet
1114,4-fold
1115,severe-end-stage
1116,epinephrine
1117,narrow
1118,hyperkalemia
1119,impact
1120,rvpo
1121,stretch
1122,lc-ms
1123,revealed
1124,hyperlipidaemia
1125,decompensation
1126,hypoalbuminemia
1127,halt
1128,walking
1129,bridge
1130,refill
1131,peptide
1132,insertion
1133,individuals and organizations
1134,lateral wall
1135,valve
1136,effect
1137,open-label
1138,non-ischemic
1139,stenosis
1140,high-volume
1141,discussions
1142,peptide levels
1143,mutant
1144,quintiles
1145,study period
1146,right ventricle
1147,metric
1148,absolute change
1149,deferred
1150,lessons
1151,eligibility
1152,separate
1153,multicenter
1154,outpatient settings
1155,regulatory
1156,lad
1157,stent
1158,stay
1159,e'septal
1160,factors
1161,liver
1162,copd
1163,subset
1164,compliance
1165,research
1166,catabolism
1167,contractility
1168,currents
1169,activity
1170,summary
1171,sst2
1172,cross-linking
1173,wedge
1174,composite
1175,slow
1176,underlying
1177,procedure
1178,cited
1179,shunts
1180,blood loss
1181,intake
1182,following
1183,sodium
1184,bet
1185,publications and presentations
1186,anthracycline-treated
1187,reverse
1188,downregulation
1189,stored
1190,high-risk
1191,conscious
1192,once
1193,expansion
1194,consumption
1195,periods
1196,defined
1197,left ventricular assist
1198,health
1199,contributed
1200,transferred
1201,penalties
1202,ratios
1203,associated
1204,reliability
1205,immunoreactive
1206,driving
1207,lbbb
1208,triangular resection
1209,obese
1210,afterload
1211,time
1212,tracked
1213,deficits
1214,vasculature
1215,pulmonary hypertension
1216,pathobiology
1217,left atrium
1218,responsible
1219,clinics
1220,grading
1221,ejection fraction
1222,beat-to-beat
1223,albumin levels
1224,erc
1225,new-user
1226,difficult
1227,end points
1228,slope
1229,cause of mortality
1230,transcription factors
1231,untranslated
1232,diuretic
1233,developed
1234,clinical benefit
1235,inroads
1236,phosphorylation
1237,heart rate
1238,anti-neoplastic
1239,biopsies
1240,nodularity
1241,resistant
1242,depresses
1243,scores
1244,skilled
1245,short-term
1246,neglected
1247,recovery period
1248,with
1249,publicly
1250,contractile
1251,lesion
1252,resulted
1253,adenoviral
1254,compute
1255,rotor
1256,pulseless
1257,underwent
1258,divided
1259,later
1260,experience
1261,uptitrations
1262,mir-25
1263,ascertained
1264,embryonic
1265,dnx
1266,parasympathetic
1267,pro-adrenomedullin
1268,obstruction
1269,coated
1270,concern
1271,dogs
1272,internal
1273,myocardial
1274,lower peak
1275,guiding
1276,organ failure
1277,subpulmonary
1278,methotrexate
1279,subcellular
1280,conjunction
1281,reproducible
1282,investigation
1283,incident
1284,timing
1285,fat loss
1286,index admission
1287,expressed
1288,left ventricular tissue
1289,significant improvements
1290,normalization
1291,delayed
1292,single-centre
1293,contextual framework
1294,rise
1295,carbohydrates
1296,unclear
1297,cytoskeleton
1298,blockers
1299,exclusion criteria
1300,separate scale
1301,sodium-restricted
1302,perioperative
1303,mr
1304,halts
1305,initiation
1306,mutually exclusive
1307,motions
1308,refuse
1309,ivabradine-treated
1310,structure
1311,community
1312,myofiber
1313,decompensated
1314,mandate
1315,adjunctive treatment
1316,reprogramming
1317,downward
1318,uptitration
1319,exerted
1320,post-transplant
1321,hf-ref
1322,viable
1323,ventricular
1324,collect
1325,quick
1326,contractile efficiency
1327,dt
1328,moderate-quality
1329,cost-minimization
1330,beats
1331,at
1332,prodrug
1333,mrna
1334,coupling
1335,regression models
1336,distinguish
1337,testosterone
1338,idiopathic
1339,recruitment
1340,trigger
1341,impairment
1342,breath-holding
1343,aldosterone
1344,anemic
1345,skinfold thickness
1346,exercise-induced
1347,pump failure
1348,recruited
1349,women
1350,risk of stroke
1351,year
1352,direct
1353,followed
1354,effectiveness
1355,recovery
1356,proteins
1357,nuts
1358,hospitalisation
1359,trends
1360,np
1361,pioglitazone
1362,e'lateral
1363,high-fat
1364,hfvt(+)
1365,supplementation
1366,eplerenone
1367,change scores
1368,echocardiograms
1369,nine pigs
1370,cm2
1371,decrement
1372,individual scales
1373,anemia
1374,undecided
1375,act
1376,unilateral renal
1377,behavioural-change
1378,early-onset
1379,adaptive
1380,guideline-recommended
1381,supplemented
1382,financial incentives
1383,hemoglobin
1384,decade
1385,statistic
1386,excursion
1387,update
1388,segment
1389,swine
1390,angina
1391,questioned
1392,survivors
1393,fixed-rate
1394,block
1395,opposed
1396,re-hospitalization
1397,issues
1398,underperfusion
1399,groups
1400,first-in-class inhibitor
1401,post-pd
1402,multiparametric
1403,vena cava
1404,reviewers
1405,rationale
1406,three
1407,rotation
1408,was
1409,pairwise
1410,pump-exchange
1411,channelopathies
1412,for
1413,well-being
1414,bnp
1415,resistance to pressure-overload-induced
1416,long-term survival
1417,elevation
1418,raloxifene
1419,misdiagnosis
1420,nonterminal epitopes
1421,antihyperglycemic agents
1422,raloxifene-treated
1423,carvedilol
1424,factor-Î²
1425,antitachycardia
1426,exogenous
1427,no
1428,transcriptional
1429,aim
1430,iron-deficient
1431,rat
1432,suppression
1433,project
1434,action potentials
1435,ablation
1436,per
1437,hf-action
1438,transgenic
1439,curve
1440,spite
1441,working hearts
1442,evidence-based
1443,i.p.
1444,play
1445,lower
1446,aging
1447,positive
1448,lesions
1449,humanized
1450,intolerance
1451,tricuspid
1452,signaling pathways
1453,production
1454,nervous system
1455,change
1456,ventricle
1457,pressure-volume conductance
1458,kidney
1459,implantation
1460,severe hypertension
1461,annual
1462,event
1463,basal rotations
1464,performed
1465,comanagement
1466,thirty-seven
1467,thickness
1468,community-based
1469,inactive
1470,endothelial-protective effects
1471,evaluations
1472,acute care hospitals
1473,investigations
1474,pre-hct
1475,sound
1476,medical
1477,rule
1478,decrease
1479,through
1480,allopurinol
1481,detrimental alterations
1482,investigating
1483,counteracted
1484,apical
1485,challenging
1486,peak
1487,sickle
1488,pressures
1489,progression
1490,delay
1491,analyses
1492,p=0.036
1493,hypotension
1494,this
1495,nonpace
1496,myofilament
1497,administrative
1498,precapillary
1499,general anaesthesia
1500,renin
1501,diagnosis
1502,compensated
1503,rate-control
1504,patent
1505,cv
1506,procedures
1507,exertion
1508,care unit
1509,interval
1510,transplant
1511,with.estimates
1512,young
1513,strategies
1514,coefficients
1515,objectives
1516,levels
1517,surgical ring
1518,dhand
1519,no change
1520,obesity
1521,time interval
1522,fatty acids
1523,outpatients
1524,infarction-related
1525,therapeutics
1526,chest
1527,confounders
1528,prescriptive
1529,provision
1530,pathway
1531,atrial
1532,old
1533,aortic pressure
1534,bypass
1535,congestive
1536,fontan
1537,off-pump
1538,prevention
1539,workload
1540,echocardiography
1541,vasopressin
1542,failing heart
1543,v.6.2
1544,inotropic
1545,adoption
1546,reducing
1547,discrepancy
1548,oht
1549,cost-effective
1550,shortening
1551,hemocompatibility
1552,nonsurvivors
1553,decoy
1554,unchanged
1555,bisphosphonates
1556,cost per patient
1557,value=0.027
1558,collagen
1559,arrhythmia
1560,specialty hospital
1561,binding
1562,inotropes
1563,commoner
1564,norepinephrine-induced
1565,pacing
1566,cuff
1567,improved
1568,wall thickness
1569,repression
1570,heart dilatation
1571,trials-enriching
1572,decile
1573,exercise capacity
1574,clinical
1575,inflow
1576,evaluated
1577,late-onset
1578,pilot
1579,hemodynamic
1580,postoperative
1581,ref
1582,transient
1583,periprocedural
1584,quality-adjusted
1585,new-onset
1586,decongestion end point
1587,myosin
1588,function
1589,medicaid
1590,department
1591,carries
1592,framework
1593,left ventricle
1594,study-related
1595,protective effects
1596,embedded
1597,nonfailing
1598,egfr
1599,mrnas
1600,care management
1601,role
1602,plays
1603,interrelated
1604,recreational
1605,overexpressing
1606,pre-participation screening
1607,non-linear
1608,impaired
1609,tobacco
1610,treatable
1611,coding
1612,t1
1613,subdomains
1614,debate
1615,joint effect
1616,line
1617,surrogates
1618,exposed
1619,athletes
1620,pacing-induced
1621,doxorubicin
1622,consultations and procedures
1623,monitoring devices
1624,pb
1625,resulting
1626,drive
1627,readmission rates
1628,ultrastructural changes
1629,diuretics
1630,combination
1631,eo-cfus
1632,edge-to-edge
1633,drives
1634,remarkable
1635,hfvt(-)
1636,persistent
1637,prescribing
1638,failing interventions
1639,composite endpoint
1640,clinical change
1641,exchange
1642,biomarker-guided
1643,decisions
1644,examined
1645,consensus
1646,paced
1647,conduction
1648,perturbed bone
1649,study design
1650,contrast
1651,decreasing
1652,filling
1653,hr
1654,trials
1655,initiatives
1656,dialysis
1657,conditions
1658,extubated
1659,tactics
1660,stroke
1661,rv failure
1662,excluded
1663,enrollment
1664,placebo
1665,office-based
1666,investigated
1667,anthracycline
1668,glomerular
1669,expertise
1670,accompany
1671,myocardial function
1672,data
1673,plasty
1674,systematic review
1675,case-control
1676,upstream signal
1677,retrieved
1678,practices
1679,testing
1680,modality
1681,limits
1682,arrhythmias
1683,uncommon
1684,coagulability
1685,regulated
1686,primary care clinicians
1687,kidney index
1688,single-center
1689,therapies
1690,second
1691,genetic
1692,co-morbidity
1693,post-aac
1694,based
1695,turbulence
1696,long
1697,noninvasive
1698,out-patient
1699,marked
1700,circulatory assist
1701,non-biological
1702,instability
1703,pattern
1704,noncardiovascular
1705,health benefits
1706,shortcomings
1707,rs10927887
1708,bleeding
1709,adaptive response
1710,infrequent
1711,right heart
1712,management
1713,midpapillary level
1714,samples
1715,histological
1716,m2
1717,non-hf
1718,blood
1719,concomitant
1720,ring
1721,reversal
1722,unplanned
1723,centre
1724,2-fold
1725,financial
1726,external
1727,indicators
1728,delineated
1729,intervention
1730,left-to-right
1731,phenylephrine-induced
1732,reveals
1733,tac-induced
1734,ros
1735,contemporary
1736,mixed
1737,advanced heart failure
1738,methodology
1739,mouse
1740,controls
1741,result
1742,connection
1743,overload
1744,lusitropic
1745,prescribed
1746,throughput
1747,uncontrolled
1748,2-vessel
1749,engage
1750,median rate
1751,extract
1752,mechanism
1753,logistic
1754,pre-pd
1755,resolved
1756,cutoff level
1757,years
1758,profoundly
1759,moderate-intensity
1760,deter
1761,muscle (31)p
1762,hypertensive
1763,data show
1764,date
1765,transmitral
1766,limits of agreement
1767,bpm
1768,clinical setting
1769,objective
1770,levitated
1771,affects
1772,exhaustion
1773,derive
1774,anaerobic
1775,germline
1776,warrants
1777,neurotransmission
1778,event-free rate
1779,conclusion
1780,stressors
1781,venous
1782,bridging
1783,insufficiency
1784,long axis
1785,peak oxygen
1786,ethnic groups
1787,dilatation
1788,denervation
1789,free-breathing
1790,up-regulated
1791,weak
1792,congenital lesions
1793,age
1794,functional
1795,costs
1796,point
1797,ng
1798,figure
1799,et
1800,susceptibility
1801,rcts
1802,clinic
1803,expenditures
1804,drugs
1805,low-dose
1806,medical treatment
1807,feasibility
1808,beneficial effect
1809,male
1810,refractory right heart failure
1811,angiography
1812,exacerbated
1813,contractile response
1814,briefing
1815,phosphocreatine
1816,dl
1817,hearts
1818,accessory
1819,pathological heart disease
1820,prolapse
1821,dithiothreitol
1822,atrial pacing
1823,modern society
1824,at-risk
1825,aforementioned
1826,hemodynamic alterations
1827,transverse
1828,medical management
1829,trans
1830,post-acute care
1831,ethically
1832,communicate
1833,intention-to-treat
1834,hno
1835,poorly
1836,revascularization
1837,myocyte
1838,replacement
1839,infarcted
1840,protective mechanisms
1841,transfusion
1842,special treatment
1843,heart
1844,anti-oxidant
1845,eseptal
1846,s'septal
1847,cost-effectiveness
1848,at the apex
1849,coefficient
1850,terms
1851,limitation
1852,event-free
1853,indeterminable
1854,hemodynamic disorder
1855,stimulated
1856,myofibre
1857,adiponectin
1858,hemolysis
1859,high-density
1860,writer
1861,heart failure-related
1862,advocate
1863,blood flow
1864,public
1865,follow-up
1866,twist
1867,walk test
1868,well-recognised
1869,high
1870,mistargeting
1871,thrombotic
1872,overexpress
1873,deals
1874,offset
1875,feasible
1876,breast
1877,outflow
1878,chemotherapy-induced
1879,relaxation
1880,low-frequency
1881,calls
1882,post-hct
1883,resting hemodynamics
1884,connected
1885,low
1886,observed
1887,measurements
1888,follow
1889,post hoc
1890,epitopes
1891,major branches
1892,hg
1893,non-aas
1894,risk
1895,absorption
1896,evaluate
1897,factorial
1898,slowness
1899,antirheumatic
1900,low-volume
1901,no changes in right
1902,double-blind
1903,regulator
1904,race
1905,recurrent
1906,activators
1907,quality
1908,biomedical
1909,interleukin
1910,weight
1911,monitoring
1912,endopeptidase
1913,case-fatality rate
1914,signaling
1915,echocardiographic
1916,growth
1917,intubation rates
1918,blood-flow
1919,circulating
1920,professionals
1921,treatments
1922,pf
1923,downstream signalling
1924,potassium level
1925,interconnected
1926,lower btes
1927,home environment
1928,regulation
1929,databases
1930,treated
1931,occurred
1932,overweight
1933,treatment
1934,rest
1935,bradycardic
1936,washout
1937,anesthetized
1938,men
1939,measures
1940,abolished
1941,interquartile
1942,self-management
1943,yield
1944,unloading
1945,exhibited
1946,not
1947,cyclase
1948,slower
1949,elucidate mechanisms
1950,primary mechanism
1951,hospital admission
1952,activation
1953,enrolled
1954,amenable
1955,purpose of review
1956,echo-doppler
1957,hct
1958,small
1959,course
1960,complex
1961,pressure-overload-induced
1962,functions
1963,income
1964,p70s6k-ser
1965,pump
1966,defibrillator
1967,cardioverter
1968,advanced management
1969,processes
1970,case-control analysis
1971,correlated
1972,systems level
1973,matched-pairs
1974,deficiency
1975,downregulated
1976,non-invasively
1977,intermediate
1978,higher
1979,benefits
1980,mediating
1981,clear
1982,explant-derived
1983,o2
1984,add-on
1985,evidenced
1986,hscrp
1987,distance
1988,health per capita
1989,waist
1990,myocardial oxygen
1991,p38
1992,double-knockout
1993,hand
1994,hall
1995,severe
1996,albumin level
1997,calreticulin
1998,well-treated
1999,published
2000,normal
2001,sensitivity
2002,nondiabetic
2003,article
2004,outcome
2005,thromboembolic
2006,rankings
2007,left ventricular
2008,linked
2009,diameters
2010,gait
2011,atropine
2012,regulates
2013,beneficial
2014,serum
2015,be
2016,evolving
2017,muscle-wasting
2018,angiotensin
2019,filling pressures
2020,factor
2021,demographics
2022,imbalance
2023,activated
2024,age-by-lvef
2025,ages
2026,energy
2027,social
2028,methylatropine
2029,phase
2030,deficit
2031,overlapping
2032,acid
2033,trainings per week
2034,formed
2035,left heart twist
2036,expressing
2037,mapping
2038,heavy chain
2039,degenerative
2040,arm
2041,events
2042,immunohistochemistry
2043,practice-level variation
2044,key
2045,circulatory arrest
2046,aimed
2047,eligibility status
2048,end-diastolic
2049,overstimulation
2050,single-payer
2051,congenital heart
2052,rhythm-control
2053,stage
2054,mechanical circulatory
2055,acetyl-lysine
2056,group
2057,dissemination
2058,median
2059,claims
